Monopar Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNPR research report →
Range $105 – $145
Price Chart
About the company
Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
- CEO
- Chandler D. Robinson
- IPO
- 2019
- Employees
- 22
- HQ
- Wilmette, IL, US
Get TickerSpark's AI analysis on MNPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $522.79M
- P/E
- -33.35
- Fwd P/E
- 124.72
- PEG
- 1.17
- P/S
- 0.00
- P/B
- 5.09
- EV/EBITDA
- -25.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -13.08%
- ROIC
- -16.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-16,704,415
- Net Income
- $-13,716,894+12.0%
- EPS
- $-1.85-36.0%
- OCF Growth
- -90.5%
- FCF Growth
- -90.5%
- 52W High
- $124.82
- 52W Low
- $50.07
- 50D MA
- $106.46
- 200D MA
- $76.50
- Beta
- 1.50
- RSI (14)
- 21
- Avg Volume
- 216.34K
No earnings-call transcripts are available for MNPR yet.
- Free Float
- 62.1%
- Shares Outstanding
- 6.70M
- Float Shares
- 4.16M
of shares held by institutions
82 13F filers
Buy/sell ratio 0.48. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 1.32M | 0 |
| Jupiter Topco LLC | 1.31M | ▲ 1.31M |
| Ra Capital Management, L.P. | 667.21K | 0 |
| Blackrock, Inc. | 348.82K | ▲ 32.25K |
| Deerfield Management Company, L.P. (Series C) | 323.75K | 0 |
| Saturn V Capital Management LLC | 311.98K | ▼ 33.65K |
| Vanguard Group Inc | 293.82K | ▲ 85.60K |
| Siren, L.L.C. | 270.12K | 0 |
| Adar1 Capital Management, LLC | 217.59K | ▼ 46.68K |
| Polar Capital Holdings PLC | 214.47K | ▼ 12.06K |
| Vanguard Capital Management LLC | 209.71K | ▼ 8.75K |
| Adage Capital Partners Gp, L.L.C. | 209.19K | ▼ 100.00K |
Held by 112 ETFs
Biggest fund positions in MNPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | STARR CHRISTOPHER M | other | 8,400 |
| Oct 1, 26 | STARR CHRISTOPHER M | sell | 4,631 |
| Oct 1, 26 | STARR CHRISTOPHER M | other | 8,400 |
| Oct 1, 26 | STARR CHRISTOPHER M | sell | 2,970 |
| Oct 1, 26 | STARR CHRISTOPHER M | sell | 799 |
| Sep 30, 26 | Cittadine Andrew | other | 4,384 |
| Sep 30, 26 | Cittadine Andrew | other | 1,944 |
| Sep 30, 26 | Cittadine Andrew | other | 4,384 |
| Sep 30, 26 | Robinson Chandler | other | 9,801 |
| Sep 30, 26 | Robinson Chandler | other | 4,344 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MNPR coverage
Recent articles, reports, and earnings notes.
No research on MNPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNPR report →Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
defenseworld.net · Aug 24
Monopar Appoints Jeffrey D. Kent, M.D.
globenewswire.com · Aug 19
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
seekingalpha.com · Aug 18
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
247wallst.com · Aug 13
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Aug 12
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
globenewswire.com · Jul 22
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
globenewswire.com · Jul 20
Monopar Therapeutics: ALXN1840's Bull Case Has Improved
seekingalpha.com · Jul 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.